PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

作者: Lisa Bodei , Mark S. Kidd , Aviral Singh , Wouter A. van der Zwan , Stefano Severi

DOI: 10.1007/S00259-019-04601-3

关键词:

摘要: … biomarker is a pharmacodynamic or response biomarker [8]. The … At this time, the response assessment for PRRT is based on … transcript assay (PPQ) that predicted tumor response to …

参考文章(32)
Lisa Bodei, Marta Cremonesi, Chiara M. Grana, Nicola Fazio, Simona Iodice, Silvia M. Baio, Mirco Bartolomei, Dario Lombardo, Mahila E. Ferrari, Maddalena Sansovini, Marco Chinol, Giovanni Paganelli, Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 38, pp. 2125- 2135 ,(2011) , 10.1007/S00259-011-1902-1
M.Ö. Öksüz, L. Winter, C. Pfannenberg, G. Reischl, K. Müssig, R. Bares, H. Dittmann, Peptide receptor radionuclide therapy of neuroendocrine tumors with Y-90-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of Ga-68-DOTATOC? Diagnostic and interventional imaging. ,vol. 95, pp. 289- 300 ,(2014) , 10.1016/J.DIII.2013.07.006
Samer Ezziddin, Jonas Lohmar, Charlotte J Yong-Hing, Amir Sabet, Hojjat Ahmadzadehfar, Guido Kukuk, Hans-Jürgen Biersack, Stefan Guhlke, Karl Reichmann, None, Does the Pretherapeutic Tumor SUV in 68Ga DOTATOC PET Predict the Absorbed Dose of 177Lu Octreotate? Clinical Nuclear Medicine. ,vol. 37, pp. e141- e147 ,(2012) , 10.1097/RLU.0B013E31823926E5
S. Ezziddin, M. Attassi, C. J. Yong-Hing, H. Ahmadzadehfar, W. Willinek, F. Grunwald, S. Guhlke, H.-J. Biersack, A. Sabet, Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate The Journal of Nuclear Medicine. ,vol. 55, pp. 183- 190 ,(2014) , 10.2967/JNUMED.113.125336
A. R. Haug, C. J. Auernhammer, B. Wangler, G. P. Schmidt, C. Uebleis, B. Goke, P. Cumming, P. Bartenstein, R. Tiling, M. Hacker, 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors The Journal of Nuclear Medicine. ,vol. 51, pp. 1349- 1356 ,(2010) , 10.2967/JNUMED.110.075002
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L. Kam, Casper H. van Eijck, Martijn van Essen, Peter P. Kooij, Richard A. Feelders, Maarten O. van Aken, Eric P. Krenning, Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival Journal of Clinical Oncology. ,vol. 26, pp. 2124- 2130 ,(2008) , 10.1200/JCO.2007.15.2553
Maria A. Kouvaraki, Jaffer A. Ajani, Paulo Hoff, Robert Wolff, Douglas B. Evans, Richard Lozano, James C. Yao, Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas Journal of Clinical Oncology. ,vol. 22, pp. 4762- 4771 ,(2004) , 10.1200/JCO.2004.04.024